Lupin gets USFDA EIR for Nagpur facility
Mumbai: Global pharma major Lupin Limited today announced that the company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its new injectable facility located in Nagpur, India.
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022.
“We are very happy to have received the EIR for our Nagpur injectable facility from the USFDA,” said Nilesh Gupta, Managing Director, Lupin. “Our state-of-the-art injectable facility at Nagpur is designed to the highest quality standards and adheres to international regulations with advanced technology and equipment. We are committed to bringing an important portfolio of injectables addressing unmet needs from the facility.”
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.